Mental Health Research Institute (Melbourne)

Arcade Therapeutics and UT Austin Jointly Announce a $3.8M NIMH Grant to Fund Large Clinical Trial Testing the Efficacy of ABM-02, The First Game-Based Digital Therapeutic for Major Depressive Disorder

Retrieved on: 
Wednesday, July 26, 2023
Arcade, Depression, University, R01, Clinical trial, Mental Health Research Institute (Melbourne), Mental health, DSM-IV codes, NIMH, National Institute of Mental Health, Trial of the century, ABM, MDD, 1996-10-24 Frank Erwin Center, University of Texas, Austin, TX, Patient, University of Texas at Austin, Entrepreneurship, Principal, FDA, Therapy, News, National Institute for Health and Care Excellence, Pharmaceutical industry, Psychology, Center for Transportation Research UT Austin

NEW YORK, July 26, 2023 /PRNewswire/ -- Arcade Therapeutics, a leading developer of game-based therapies for mental health, and University of Texas Austin's Institute for Mental Health Research, a leading research center in the field of depression, jointly announced the closing of a $3.8M grant from the National Institute for Mental Health (NIMH) to support clinical investigation and validation of ABM-02 as a game-based treatment for Major Depressive Disorder (MDD).

Key Points: 
  • The study will assess 600 participants suffering from depression across these three, randomly-assigned arms, and will be the largest and most rigorous test of ABM for depression ever completed.
  • Arcade intends to use findings from this ambitious clinical study to support their FDA submission of ABM-02 as the first game-based treatment for Major Depressive Disorder.
  • This news follows the recent success of a clinical trial investigating Arcade's flagship therapeutic game, StarStarter Rx (aka ABM-01) as the first game-based treatment for the most prevalent anxiety condition, Social Anxiety Disorder.
  • Co-Founder and Chief Science Officer of Arcade Therapeutics, Tracy Dennis-Tiwary PhD added, "Only half of those suffering from depression seek and receive treatment.

OM1 Expands Mental Health Offering With Real-World Datasets Including Schizophrenia and Bipolar Disorder

Retrieved on: 
Thursday, March 2, 2023
General Health, Health Technology, Health, Mental Health, Depression, Overalls, FDA, Research, Schizophrenia, Pharmacy, Mental health, Patient, Anxiety, DSM-IV codes, Mental, HIV disease progression rates, OM1, Bipolar, Mental Health Research Institute (Melbourne), Data, Bipolar disorder, Nursing, Neuroscience

OM1 a leading real-world data, outcomes and technology company with a focus on chronic conditions, today announced the enhancement of its Mental Health and Neuroscience Real-World Data to include schizophrenia and bipolar disorder.

Key Points: 
  • OM1 a leading real-world data, outcomes and technology company with a focus on chronic conditions, today announced the enhancement of its Mental Health and Neuroscience Real-World Data to include schizophrenia and bipolar disorder.
  • By introducing enhanced data from more than 148,000 patients with schizophrenia and bipolar, OM1 paves the way for unmatched clinical depth and novel research insights.
  • The data is part of the larger OM1 Mental Health Network of more than 3 million patients, making it the largest specialty network of its kind in the U.S.
  • To learn more about the largest Mental Health and Neuroscience data network in the U.S., please email [email protected] .

Shoppers Drug Mart puts sexual wellness in customer's hands with online launch of Canada's top-rated products

Retrieved on: 
Tuesday, February 7, 2023
Embarrassment, Shoppers Drug Mart, Woman, Blood, Sleep, Shame, Plus One, Orgasm, Social stigma, SVP, Lubricant, Health, Radar, Mental Health Research Institute (Melbourne), Grammatical mood, LELO, Oxytocin, Birth control

TORONTO, Feb. 7, 2023 /CNW/ - February 7, 2023 - Today, Shoppers Drug Mart is making sexual wellness easier for Canadians with the launch of a new selection of products – including personal massagers, vibrating bullets, lubricants and more – online and in select stores.

Key Points: 
  • TORONTO, Feb. 7, 2023 /CNW/ - February 7, 2023 - Today, Shoppers Drug Mart is making sexual wellness easier for Canadians with the launch of a new selection of products – including personal massagers, vibrating bullets, lubricants and more – online and in select stores.
  • A recent survey by Shoppers Drug Mart found most Canadian women are unaware of the benefits of sexual wellness to their overall health.
  • It's a positive step forward in women's sexual health to see a trusted retailer like Shoppers Drug Mart join this important conversation."
  • Today's launch includes products from SKYN, Plus One, Floravi and LELO, all of which can be found online at shop.shoppersdrugmart.ca .

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

Retrieved on: 
Thursday, August 4, 2022
Phase II, Post-traumatic stress disorder, CMPS, Goldsmith, TRD, Senior, Innovation, ASD, Clinical trial, Mental Health Research Institute (Melbourne), COMPASS, Autism, III, Investor, Columbia University Irving Medical Center, Patient, Food, Mental health, Review, II, IIB, Nasdaq, FDA, University College London Hospitals NHS Foundation Trust, Mount Sinai Hospital, Policy, Institute, South London and Maudsley NHS Foundation Trust, Research, Institute of Psychiatry, Psychology and Neuroscience, US Foods, Otsuka Pharmaceutical, Sheppard and Enoch Pratt Hospital, Anorexia nervosa, Psilocybin, Principal investigator, Slam, R, CEO, KOL, PTSD, Webcast, G&A, UC San Diego School of Medicine, Leadership, Psychology, University, Center, Partnership, King's College London, Pharmaceutical industry, Online gambling, Video game

COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2022 and gave an update on recent progress across its business.

Key Points: 
  • COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2022 and gave an update on recent progress across its business.
  • The COMPASS Pathways management team will host a conference call at 8.00am ET (13.00 UK) on 4 August 2022.
  • A live webcast of the call will be available on COMPASS Pathways website at: Second Quarter 2022 Financial Results .
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.

Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre

Retrieved on: 
Wednesday, July 13, 2022
Ketamine, Clinical trial, Chronic pain, Anxiety, Safety, Sleep, Cumming School of Medicine, Health Canada, Science, Intention, Biomass, Suicidal ideation, United States Public Health Service, Patient, CEO, Psilocybin, CSE, GLOBE, MDMA, PTSD, Depression, GMP, Mental Health Research Institute (Melbourne), Mental health, FRA, Research, University, FOR, Industry, Partnership, Memory, Pharmaceutical industry, Dietary supplement, Bloom

Our Supply Agreement with Bloom solidifies another key relationship for Optimi, said CEO Bill Ciprick.

Key Points: 
  • Our Supply Agreement with Bloom solidifies another key relationship for Optimi, said CEO Bill Ciprick.
  • Bloom Founder and CEO, Jim Parker, says the partnership between Bloom and Optimi provides an incredible opportunity to measure true GMP-produced, Canadian-sourced natural psilocybin.
  • The Bloom Psychedelic Therapy and Research Centre is a world-class research centre committed to furthering the science supporting the use of psychedelics for depression, suicidal ideation, anxiety, PTSD, and chronic pain.
  • The Parker Psychedelic Research Chair led out of the Mathison Centre for Mental Health Research & Education at the Hotchkiss Brain Institute in the Cumming School of Medicine, is furthering important research into alternative therapies for mental health.

HOPE Center Harlem to Honor Mental Health Heroes at Annual Event

Retrieved on: 
Monday, June 6, 2022
Linda, Community engagement, The Kristin Brooks Hope Center, Social work, COVID, Mental health, National Alliance on Mental Illness, Child, Central, Mental disorder, Psychiatry, Breakfast, HOPE, Solution, Adolescence, 2004 Democratic National Convention keynote address, Seventh Avenue, National Alliance, Carnegie Hall, NYU, Male, Psychotherapy, Department, United States Public Health Service, Institute, Color, Mental Hygiene, Doctorate, Mental Health Research Institute (Melbourne), Health, Medicine

NEW YORK, June 6, 2022 /PRNewswire/ -- Local and national mental health leaders will be celebrated at the HOPE Center Harlem's HOPE in Action Fundraising Awards Breakfast on June 17. Among those being honored at the 3rd annual event, sponsored by Sugar Hill Capital Partners, are Dr. Torian Easterling, First Deputy Commissioner and Chief equity Officer at the New York City Department of Health & Mental Hygiene, and Rawle Andrews Jr., Executive Director of the American Psychiatric Association Foundation (APAF).

Key Points: 
  • NEW YORK, June 6, 2022 /PRNewswire/ -- Local and national mental health leaders will be celebrated at the HOPE Center Harlem's HOPE in Action Fundraising Awards Breakfast on June 17.
  • Given the growing mental health crisis in the wake of the COVID pandemic, the urgency to identify new treatments and solutions has never been greater, the HOPE Center noted.
  • The breakfast brings together a distinguished group of doctors, mental health scholars, researchers, clinicians, and advocates who have contributed greatly to addressing the health & mental health challenges of our time.
  • The HOPE Center offers free mental health services for individuals, families, and group therapy for adults and teens focused on suicide prevention.

COMPASS Pathways plc announces first quarter 2022 financial results and business highlights

Retrieved on: 
Tuesday, May 10, 2022
ASD, Psilocybin, Society, Autism, Nasdaq, Post-traumatic stress disorder, CMPS, Biological Psychiatry (journal), IIB, Food, Psychology, South London and Maudsley NHS Foundation Trust, COMPASS, Clinical trial, Anorexia nervosa, FDA, Center, III, Institute of Psychiatry, Psychology and Neuroscience, Institute, Mental Health Research Institute (Melbourne), US Foods, PTSD, SSRI, TRD, Mental health, CEO, G&A, Pharmaceutical industry

George Goldsmith, Chairman, CEO and Co-founder, COMPASS Pathways, said, COMPASS made great progress this quarter including a productive end-of-phase II FDA meeting and we are actively working to finalise our phase III programme.

Key Points: 
  • George Goldsmith, Chairman, CEO and Co-founder, COMPASS Pathways, said, COMPASS made great progress this quarter including a productive end-of-phase II FDA meeting and we are actively working to finalise our phase III programme.
  • R&D expenses were $15.4 million for the three months ended 31 March 2022, compared with $6.9 million during the same period in 2021.
  • The COMPASS Pathways management team will host a conference call at 1.00pm UK (8.00am ET) on 10 May 2022.
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.

OM1 LAUNCHES NEW MENTAL HEALTH AND NEUROSCIENCE REAL-WORLD DATA NETWORK

Retrieved on: 
Thursday, March 31, 2022
Multiple sclerosis, Bipolar disorder, Mental health, Government, HIV disease progression rates, Massachusetts General Hospital, Central nervous system, CNS, Research, Faculty, Lists of diseases, Hospital, OM1, CEO, National Institutes of Health, Health, Psychiatry, Schizophrenia, Artificial intelligence, Industry, Technology, Mental, National, MS, Harvard Medical School, Mental Health Research Institute (Melbourne), Central nervous system disease, Depression, FDA, Patient, Medicine, Pharmaceutical industry, Medical device, Neuroscience

Real-world data with clinical depth and nuance are critically needed to understand disease progression, patient characteristics, condition subtypes and variations -- as well as the costs and clinical outcomes of new and existing treatments. These data are now available from OM1 to be used to accelerate medical research and FDA approvals of new therapies and to help partners deliver the right treatment for the right patients at the right time.

Key Points: 
  • With over 9,000 specialists and 3M patients, the OM1 Mental Health Data Network is one of the largest in the country.
  • Mental health and CNS disorders are areas of unmet and growing medical need in the U.S.
  • In particular, mental health disorders have been exacerbated by the pandemic and now constitute a national crisis.
  • The Mental Health and Neuroscience Specialty Area will allow OM1 to have unparalleled focus on data-driven solutions to help life sciences companies, payers, providers, and government agencies.

COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK

Retrieved on: 
Thursday, March 24, 2022
COMPASS, NHS, Anorexia nervosa, Mental health, IIB, Post-traumatic stress disorder, Bethlem Royal Hospital, Growth, Clinical trial, PTSD, South London and Maudsley NHS Foundation Trust, Research, CMPS, Certification, Government, Institute of Psychiatry, Psychology and Neuroscience, CEO, Food, Maudsley Hospital, Health, Center, Mental Health Research Institute (Melbourne), TRD, US Foods, Institute, Nasdaq, FDA, Slam, Psychology, Patient, Partnership, Medicine, Pharmaceutical industry

COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has formed a long-term strategic partnership to launch The Centre for Mental Health Research and Innovation (the Centre) to accelerate psychedelic research and develop new models of care for mental health in the UK.

Key Points: 
  • COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has formed a long-term strategic partnership to launch The Centre for Mental Health Research and Innovation (the Centre) to accelerate psychedelic research and develop new models of care for mental health in the UK.
  • We are grateful to be able to play a part in this, and to be working with SLaM and the IoPPN, UK leaders in patient care and research in mental health.
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.
  • The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at Kings is the premier centre for mental health and related neurosciences research in Europe.

Optimi Health Appoints Principal Investigator for Clinical Dosing Study

Retrieved on: 
Tuesday, October 19, 2021
Psilocybin, Clinical trial, Compliance, University, CSE, Psilocin, Director, IMPACT, Full, Clinical Practice, Health Canada, Doctor of Philosophy, Precision medicine, Good clinical practice, Sale, Board, Fungus, Education, Program, Research, Mental Health Research Institute (Melbourne), Principal investigator, III, FDR, Safety, Psychiatry, Knowledge, GLOBE, Health, Patient, GCP, Efficiency, Science, HBI, Principal, Company, FRA, Pharmaceutical industry

The Optimi team is clearly focused on achieving specific quantifiable results, and Im delighted to have the opportunity to help ensure the study proceeds efficiently.

Key Points: 
  • The Optimi team is clearly focused on achieving specific quantifiable results, and Im delighted to have the opportunity to help ensure the study proceeds efficiently.
  • A Principal Investigator (PI) is the physician who leads the conduct of a clinical trial at a study site.
  • Responsibilities include ensuring the study is run in accordance with national regulatory agency requirements and "Good Clinical Practice" (GCP).
  • The program works to design, support, execute, and report on the clinical trial process in conjunction with a Principal Investigator.